Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...

Gilead Sciences delivered a better-than-expected second quarter, propelled by the strong performance of its HIV portfolio and ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 1 ...

Gilead Sciences has secured approval from the United States health authorities for its new HIV prevention injection, Yeztugo, but concerns are growing over its steep price tag.

JPMorgan (NYSE: JPM) told investors in a note Monday that Eli Lilly & Co. (NYSE: LLY) shares are its “top pick” among U.S.

Gilead Sciences, Inc. (NASDAQ:GILD) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Gilead Sciences, Inc.

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative breast cancer (TNBC), but could be heading for use in previously ...

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular glue programme, as Sanofi buys into another. The agreement with Gilead ...

Gilead Sciences, Inc. (GILD) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.

Wall Street traders sent stocks down from all-time highs as data showed mixed indications on how American consumers are ...

The Newspaper for Every Jewish Home.Biotech giant and cash-rich Gilead Sciences will open a marketing office in Israel, Globes Business news reported, making the company the first new generation ...